Prostate neoplasm

This trial tests a personalized therapy called GT201, made from a patient's own tumor-infiltrating lymphocytes (TILs). The goal is to see if these immune cells, grown in the lab and infused back into the patient, can shrink or eliminate advanced solid tumors. The study includes a…

This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …

This trial is testing an investigational drug called SHR-8203, given as an injection, in people with advanced or metastatic solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the safest dose, understand ho…

This study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…

This Phase II trial tests whether an immune-boosting drug (N-803) alone or combined with a vaccine (ETBX-071) can lower PSA levels in men whose prostate cancer has returned after targeted radiation therapy. Participants receive up to eight cycles of treatment and are followed for…

This trial is testing a new way to deliver radiation therapy for prostate cancer. Instead of standard radiation, it uses MRI to precisely target the tumor, potentially sparing healthy tissue and reducing side effects. The study will include about 20 adults with early-stage prosta…

This trial tests whether a supervised strength and conditioning program can protect the heart and reduce inflammation in men with prostate cancer who are receiving radiation and hormone therapy. Participants will follow a structured exercise routine, and researchers will measure …

This study tests a new drug called SX-682 (a tablet) combined with the chemotherapy docetaxel in people whose head/neck, salivary gland, or prostate cancer has spread or returned after treatment. The goal is to find the right dose and see if the combination shrinks tumors. About …

This phase 2 trial tests a combination of a vaccine (TriAdeno) and an immune-boosting drug (N-803) in 52 men with early-stage, low- or medium-risk prostate cancer who are currently on active surveillance. The vaccine targets three proteins found in prostate cancer cells, while N-…

This phase 2 trial is testing an experimental drug called xaluritamig in men with metastatic castrate-resistant prostate cancer who had only a partial or stable response to lutetium-177 therapy. The goal is to see if xaluritamig can shrink tumors or lower PSA levels. About 30 par…

This study tests a device called Vanquish that uses water vapor (steam) to destroy prostate cancer tissue in men with Grade Group 3 intermediate-risk prostate cancer. Fifty participants will receive the treatment and be followed for two years to see if the cancer is reduced and t…

This early-phase trial is testing whether combining two immune-based treatments—Sipuleucel-T, a vaccine made from a patient's own immune cells, and N-803, a drug that boosts immune activity—is safe and tolerable for men with metastatic prostate cancer that has stopped responding …

This trial is testing an experimental therapy called CRG-150, which uses a patient's own immune cells that have been gene-edited to potentially fight cancer. The study includes adults with advanced HR-positive/HER2-negative breast cancer, triple-negative breast cancer, or prostat…

This phase 3 trial is testing whether giving men with metastatic prostate cancer half the standard dose of certain hormone therapies (called ARPIs) can be just as effective as the full dose, while causing less fatigue and fewer treatment stoppages. About 1,500 men with prostate c…

This study tests whether adding a radioactive drug called 177Lu-PSMA-617 to standard radiation therapy can allow men with high-risk localized prostate cancer to take hormone therapy for only 6 months instead of the usual 24 months. The goal is to see if this approach is as effect…

This early-stage trial is testing an investigational drug called BR113 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive BR…

This early study tests a new drug (177Lu-DTPA-SC16.56) that delivers radiation directly to cancer cells in people with small-cell lung cancer or neuroendocrine prostate cancer that has come back after standard chemotherapy. The main goal is to find the safest dose and see if the …

This early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…

This early-stage trial is testing an experimental drug called JNJ-98768111 in people with advanced prostate cancer that has spread to other parts of the body. The drug is designed to seek out and attach to a protein called KLK2 on prostate cancer cells, delivering a toxic agent d…

This early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of che…

This trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…

This study compares a robotic water-jet procedure called Aquablation to active surveillance (close monitoring) in 333 men with low- or intermediate-risk localized prostate cancer. The goal is to see if Aquablation can better prevent cancer from progressing to a more serious grade…

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This early-stage trial is testing an experimental drug called SHR-6914 in men with prostate cancer that has spread to other parts of the body. The main goal is to see if the drug is safe and tolerable, and to find the right dose for future studies. Participants must have a confir…

This trial is testing whether using microultrasound to guide a radiation boost to cancerous spots inside the prostate can reduce side effects compared to standard radiation therapy. Men with intermediate-risk prostate cancer will receive stereotactic body radiation therapy (SBRT)…

This trial tests whether adding darolutamide to standard chemotherapy and hormone therapy before prostate removal can improve long-term outcomes for men with locally advanced prostate cancer. Participants receive either the triple combination or the standard two-drug regimen for …

This trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in…

This trial is investigating whether an experimental drug called XNW5004, when combined with standard anti-tumor therapies, can help control advanced prostate cancer. The study involves men with prostate cancer that has spread. Researchers are looking at how safe the combination i…

This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…

This trial explores whether semaglutide, a drug approved for weight management, can affect tumor biology when given for 3 to 6 months before prostate removal surgery. About 20 men with intermediate-risk localized prostate cancer and a BMI over 35 will receive weekly injections. R…

This trial is testing an experimental drug called ML-016, a nanoparticle form of the chemotherapy doxorubicin, in people with advanced solid tumors that have spread to the lungs or liver. The study aims to find the safest dose and see whether the drug can shrink tumors or slow th…

This early-phase trial explores whether PSMA PET scans can help doctors adjust radiation therapy for men with prostate cancer that has spread to 4 to 20 spots in the body. Participants receive standard hormone therapy plus a special PET scan, then targeted radiation to all visibl…

This study tests a new drug combination (BL-B01D1 plus other treatments) in 180 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if the combination can delay cancer growth or shrink tumors. Part…

Hormone therapy for prostate cancer often causes muscle loss, which may weaken the immune system by reducing a key signalling protein called IL-7. This trial tests whether a 12-week supervised strength training programme can prevent muscle loss and raise IL-7 levels in men receiv…

This early-phase trial tests an experimental drug called ISM5939, taken as a pill, in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with chemotherapy (cisplatin or doce…

This trial tests an experimental drug called HMPL-A830 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in more people to see if it can shrink tumors. The goal is to un…

This early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…

This trial tests a care package called the 'WARNING Pack' for people aged 75 and older with cancer. The pack helps doctors spot early signs of age-related problems and provides a guide for managing them. The goal is to prevent a decline in quality of life and reduce the risk of g…

This study looks at whether testosterone replacement therapy (TRT) is safe for men with low-risk prostate cancer who also have low testosterone. Researchers will monitor 35 men for 12 months to see if the cancer gets worse or if they need stronger treatment. The goal is to help m…

This study looks at how effective the drug Pluvicto (177Lu-PSMA-617) is in treating men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. Researchers will analyze medical records from over 1,000 patients …

This phase II pilot trial is testing a three-drug combination—radium-223, darolutamide, and standard hormone therapy—in men with high-volume metastatic hormone-sensitive prostate cancer. The goal is to see if adding radium-223 as maintenance therapy after initial treatment can im…

This phase 1 trial tests an experimental drug called TJ037130 in adults with advanced solid tumors, including ovarian, gastric, and endometrial cancers that have spread. The main goal is to check the drug's safety and find the best dose for future studies. Participants receive TJ…

This study tests an experimental oral drug called elraglusib in adults with advanced solid tumors that have spread or are not responding to standard treatments. The trial aims to find the safest dose and evaluate how the body processes the drug, while also looking for early signs…

This study tests whether adding the experimental drug saruparib to standard hormone therapy can slow the growth of metastatic hormone-sensitive prostate cancer. It includes men whose cancer has not progressed after prior chemotherapy or a specific type of radiation therapy. Parti…

This study explores whether a simple blood test that measures tumor DNA (ctDNA) can help doctors decide when to stop a targeted radiation therapy called 177Lu-PSMA-617 in men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The goal is…

This trial tests a streamlined approach for men at high risk of clinically significant prostate cancer. Under one anesthesia session, doctors perform an MRI-guided biopsy, analyze the tissue immediately with rapid lab tests, and if cancer is confirmed, proceed directly to laparos…

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This early-stage trial tests an experimental therapy called GKL-006Allo, made from donor immune cells (iNKT cells), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the therapy's safety and how the body processes it.…

This study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…

This study tests whether a 12-week virtual cooking and nutrition program is practical and helpful for Hispanic prostate cancer survivors and their caregivers. Participants attend nutrition education, cooking classes, and health coaching sessions online. The goal is to see if the …

This trial tests a new drug called VBC108 in people with advanced solid tumors that have not responded to standard treatments. VBC108 is designed to attach to two specific proteins (CLDN18.2 and CDH17) found on some cancer cells and deliver a toxic payload to kill them. The study…

This study tests an experimental drug called LM-364, given alone or with another cancer drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 90 adults…

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…

This trial tests an experimental drug called HSK46256, which blocks a protein called PARP1 that helps repair DNA in cancer cells. The study includes adults with advanced solid tumors who have not responded to standard treatments. Researchers aim to find the safest dose and check …

This trial tests an experimental drug called VBC106 in people with advanced solid tumors that have not responded to standard treatments. VBC106 is designed to target two proteins (FRα and MSLN) found on some cancer cells, delivering a toxic payload directly to the tumor. The stud…

This phase 1 trial tests whether giving a higher first dose of the radioactive drug Lu-177-PSMA-617 can improve treatment for men with metastatic castration-resistant prostate cancer. The drug targets a protein on prostate cancer cells and delivers radiation to kill them. Researc…

This study tests a new treatment called VG2025, a modified herpes simplex virus designed to infect and kill cancer cells while also boosting the immune system. The trial enrolls adults with advanced solid tumors that have not responded to standard therapies and who have previousl…

This early-stage trial tests whether adding CP-PCA07 (a form of niclosamide, a drug used for tapeworm infections) to the standard drug enzalutamide can safely help men with castration-resistant prostate cancer that has stopped responding to treatment. The study involves 18 men an…

This trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…

This trial investigates whether combining a targeted radioactive drug (177Lu-PSMA-617) with a hormone therapy (darolutamide) before surgery can improve outcomes for men with high-risk localized prostate cancer. Participants receive two doses of the radioactive drug and daily horm…

This study looks at how well darolutamide (Nubeqa) plus standard hormone therapy works in Chinese men whose prostate cancer has become resistant to earlier treatment but hasn't spread. About 800 men will take part, and researchers will track PSA levels to see if the cancer is con…

This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This early-stage trial is testing a new cell therapy called GK01 in 10 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells (T cells) that are trained to attack the tumor. The main goal is to check …

This early-phase trial tests a new treatment called ML261 for people with advanced small cell lung cancer or certain neuroendocrine cancers that have not responded to standard treatments. ML261 is made from a patient's own immune cells, which are modified in a lab to better recog…

This early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…

This study tests a new drug called DEC003M, which is designed to seek out and destroy prostate cancer cells by targeting a protein called PSMA. The trial enrolls adults with advanced prostate cancer that has stopped responding to standard hormone therapy. Researchers aim to find …

This early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…

This study tests a personalized approach to hormone therapy for men with metastatic hormone-sensitive prostate cancer. The goal is to reduce treatment intensity for lower-risk patients to minimize side effects while still controlling the cancer. About 108 participants will receiv…

This phase II trial tests whether adding a targeted radiation drug (177Lu-PSMA-617) to standard hormone therapy, with or without additional hormone-blocking pills, can better control low-volume metastatic hormone-sensitive prostate cancer. The study enrolls men whose cancer has s…

This study tests whether adding precisely targeted radiation to standard hormone therapy helps men with metastatic hormone-sensitive prostate cancer. All participants first receive six months of darolutamide plus androgen deprivation therapy. Those whose cancer has not progressed…

This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…

This study tests whether a single, powerful dose of MRI-guided radiation can safely treat prostate cancer that has come back in a few lymph nodes after initial treatment. Forty-eight men will receive one 24 Gy radiation session aimed precisely at the affected nodes. The main goal…

This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…

This phase 2 trial tests a radioactive drug called terbium-161 PSMA in 60 men with metastatic prostate cancer that has worsened after standard treatments. The drug is designed to seek out and destroy cancer cells. Participants will receive three cycles of the drug, and researcher…

This study tests whether giving radiotherapy to the prostate and to cancer spots seen on PET scans can help men with metastatic prostate cancer whose PSA levels remain high after six months of hormone therapy. Participants continue their hormone treatment and receive three PSMA-P…

This study tests whether tamoxifen, a drug commonly used for breast cancer, can speed up testosterone recovery in men with prostate cancer who have completed hormone therapy (ADT). Many men experience low testosterone for months or years after stopping ADT, causing fatigue, depre…

This phase 2 trial tests a drug called sacituzumab tirumotecan in people with neuroendocrine prostate cancer, a rare and aggressive form that has progressed after platinum-based chemotherapy. The drug is given by IV infusion three times per 42-day cycle. The study measures how ma…

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…

This Phase 3 trial compares an experimental drug, QLC5508, against the standard chemotherapy docetaxel in 700 men with metastatic castration-resistant prostate cancer that has worsened after hormone therapy. The main goal is to see if QLC5508 delays cancer growth better than doce…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This early-stage trial tests a new drug, QLF4113, in about 140 men with metastatic castration-resistant prostate cancer that has spread and no longer responds to standard hormone therapy. The main goals are to find a safe dose and check for side effects, while also looking for si…

This study tests a daily pill called zanzalintinib in men with advanced prostate cancer that has stopped responding to hormone therapy and has already been treated with Pluvicto. The goal is to see if the drug can delay cancer growth or shrinkage. About 30 participants will take …

This study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …

This early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…

This long-term extension study offers continued access to several cancer drugs—including cabozantinib, atezolizumab, and nivolumab—for up to 5,000 patients who benefited from them in earlier Exelixis-sponsored trials. The study focuses on monitoring safety and ongoing clinical be…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…

This early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.

This early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …

This study tests a new drug called zanzalitinib in people with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to soft tissues or organs. The goal is to see if the drug can slow or stop cancer growth. About 19 participants will receive…

This early-phase study tests a shorter, more intense form of carbon-ion radiation for men with low- or intermediate-risk prostate cancer. Instead of the usual 12 sessions, patients receive just 6. The main goal is to check safety and side effects within 90 days. Up to 20 men will…

This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…

This early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…

This phase 3 trial tests whether daily vitamin D supplements can improve immune function and quality of life in Black/West African men with prostate cancer who have low vitamin D levels. Researchers will compare men with localized disease to those with advanced cancer, tracking i…

This early-stage trial tests a combination of two drugs—docetaxel (chemotherapy) and a radioactive compound called 177Lu-PSMA-I&T—in men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to find the safest dose of docetaxel when used with the r…

This phase 2 trial tests whether adding mevrometostat to enzalutamide can slow cancer growth in 60 men with metastatic castration-resistant prostate cancer who have already been treated with similar drugs. Participants will take both drugs orally. The main goal is to see how long…

This early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…

This early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…

This early-stage study tests a special sheet called dMD-002 that helps repair nerves damaged during prostate removal surgery for prostate cancer. About 30 men will receive either the sheet or a placebo during their robot-assisted surgery. The goal is to see if it improves erectil…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This phase 3 trial tests whether adding carboplatin to standard therapy can delay cancer growth in men with aggressive prostate cancer that has spread and has either a BRCA gene mutation or neuroendocrine features. About 330 participants will receive either standard care alone or…

This study tests a weekly, image-guided radiation therapy (SBRT) for men with very high-risk prostate cancer that may have spread to nearby lymph nodes. The treatment uses weekly CT or MRI scans to adapt the radiation dose precisely to the tumor. The main goals are to see if this…

This early-phase trial tests a radioactive drug called tin-117m-DTPA in 24 people with prostate, breast, or lung cancer that has spread to the bones. The drug is designed to deliver low-level radiation directly to bone tumors while being gentler on the bone marrow. Researchers wi…

This trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…

This early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.

This study tests a new way to give radiation for prostate cancer using only 2 treatments instead of the usual 39. Doctors will use MRI scans to see how the tumor responds after the first dose, then adjust the second dose to target the cancer more precisely. The goal is to see if …

This trial tests whether a combination of a daily erectile medication, pelvic floor exercises, aerobic exercise, dietary advice, and mental health support can improve erectile function and urinary control in men after robot-assisted prostate removal for prostate cancer. Sixty-fou…

This phase 2 trial tests an oral drug called pacritinib in 32 men with metastatic castrate-resistant prostate cancer that has worsened after standard treatments. The drug is taken twice daily, and the main goal is to see if it can delay cancer growth for at least six months. Part…

This study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…

This early-stage trial tests a new radioactive drug called 177Lu-FC516 in 13 men with advanced prostate cancer that has stopped responding to standard treatments. The drug is given every 6 weeks for up to 4 cycles. The main goals are to find the safest dose and check for side eff…

This early-stage trial tests crotoxin, a protein from rattlesnake venom, given intravenously to 24 adults with advanced solid tumors that have not responded to standard therapy. The main goal is to see if a slow dose increase can make the drug safer and better tolerated. Research…

This study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…

This study tests a new approach called Bioblation, which combines a prostate biopsy with laser ablation in a single session under local anesthesia. It is for men with severe urinary symptoms and suspected low- to intermediate-risk prostate cancer. The goal is to see if this one-s…

This study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …

This phase 2 trial tests whether adding precise external beam radiation to standard radioligand therapy can better control metastatic prostate cancer that no longer responds to hormone therapy. About 120 participants will receive either standard treatment alone or combined with t…

This early-phase trial tests whether adding two drugs (darolutamide and homoharringtonine) to standard chemo and hormone therapy can more thoroughly clear high-risk prostate cancer before surgery. About 94 men will receive the combo for 7 weeks, then have their prostate removed t…

This pilot study will test a new device that uses pulsed field ablation (PFA) to treat localized prostate cancer in 50 men aged 45 or older. The goal is to see if the procedure is safe and effective at destroying cancer cells while minimizing damage to surrounding tissue. Partici…

This study tests a personalized radiation approach for men whose prostate cancer has returned after surgery. Using PSMA PET scans, doctors will give higher radiation doses to active cancer spots and lower doses to healthy areas, all in just 5 treatments over two weeks. The goal i…

This study tests whether daily adaptive radiotherapy (ART) can safely deliver shorter, more intense radiation treatments for prostate, endometrial, cervical, and rectal cancers. About 264 participants will be randomly assigned to standard radiation or ART, which uses daily imagin…

This early study tests a new device called Alpha DaRT, which places tiny radioactive seeds directly into prostate tumors that have returned after initial treatment. The main goal is to see if it's safe, with a secondary look at whether it can control the cancer. Up to 12 men with…

This study tests a combination of darolutamide, hormone therapy, and a lower dose of the chemotherapy drug docetaxel in men with metastatic hormone-sensitive prostate cancer. The goal is to see if this approach can keep PSA levels very low (below 0.2 ng/mL) at 24 weeks while redu…

This early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …

This study tests whether adding surgery and targeted radiation to a new hormone-blocking drug (rezvilutamide) can help men whose prostate cancer has spread to a few spots (oligometastatic). 300 men will be split into three groups: one gets the drug alone, one gets drug plus surge…

This early-stage trial tests a new biologic drug, SIG001, in 66 people with advanced solid tumors. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Participants receive SIG001 intravenously every two weeks and are monitored for si…

This early-stage trial tests a new oral drug called HLX97 in 138 people with advanced solid tumors (breast, prostate, or lung cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can slow tumor g…

This study tests a drug called darolutamide, with or without hormone therapy (ADT), given before surgery for high-risk localized prostate cancer. Sixty men will be split into two groups: one gets darolutamide alone, the other gets darolutamide plus ADT for 3-6 months before robot…

This study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…

This phase 2 trial tests a drug called teverelix DP in 40 men with advanced prostate cancer. The drug works by blocking a hormone that tells the body to make testosterone, which can fuel cancer growth. The goal is to see if a specific dosing schedule can safely lower testosterone…

This early-stage trial is testing an experimental drug called GLR2037 in 65 men with metastatic prostate cancer that has spread to bones or soft tissues. The main goals are to check the drug's safety and how the body processes it. Participants will take GLR2037 daily in 28-day cy…

This early-phase study tests a new drug called QLS5308 in about 192 adults with advanced solid tumors that have spread and cannot be removed by surgery or radiation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…

This study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…

This study tests whether the drug rezvilutamide, combined with standard hormone therapy, can prevent high-risk prostate cancer from coming back after surgical removal. About 33 participants will take the pills and get injections for up to 2 years. The main goal is to see how many…

This early-stage study tests a new drug called T320 in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive T320 every two wee…

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This early-phase trial tests an experimental drug called ITC-6146RO in about 102 adults with advanced or metastatic cancers (like prostate, lung, or breast cancer) that have not improved with standard treatments. The study has two parts: first, finding a safe dose, then checking …

This early-phase trial tests a new type of cell therapy called CAR-Macrophages in 20 adults with advanced solid tumors. The immune cells are modified to target specific markers on cancer cells (HER2, PSMA, FAP) and are given by IV. The main goals are to check safety, find the bes…

This early study tests a new treatment called CAT-101, which uses a patient's own immune cells (dendritic cells) loaded with a cancer protein (mKRAS) to help the body fight tumors. It is for people with advanced pancreatic cancer or other solid tumors that have a specific KRAS mu…

This early-phase trial tests whether adding a dietary supplement called LC-K76 to standard hormone therapy is safe for men with metastatic hormone-sensitive prostate cancer. Forty men will receive the supplement plus hormone therapy for 24 weeks, then be followed for another 24 w…

This early-stage study tests a new drug (LC-K76) combined with an immunotherapy (Tislelizumab) and hormone therapy in 10 men with metastatic castration-resistant prostate cancer that has worsened after standard treatments. The goal is to check safety and see if the combination ca…

This early-phase study tests a new radioactive drug, 161Tb-LNC1011, in 15 men with advanced prostate cancer that no longer responds to hormone therapy. The drug is designed to seek out and deliver radiation directly to cancer cells. The main goals are to check safety and find the…

This phase 2 trial tests whether adding evofosfamide to standard hormone therapy can help men with castration-resistant prostate cancer that has spread. The drug targets low-oxygen areas in tumors. 35 participants will receive the drug combination and be monitored for PSA respons…

This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…

This early-phase study tests whether a new cell therapy called B7-H3 CAR T cells is safe and can help children and young adults whose solid tumors have returned or stopped responding to standard treatments. About 40 participants will receive their own immune cells that have been …

This early-stage trial tests a procedure called microtransplantation (MST) combined with chemotherapy in 10 adults with advanced or relapsed solid tumors. The goal is to see if MST can help control the disease and improve recovery of blood cells after chemo. The study focuses on …

This study tests whether a remote temperature monitor can help detect fever early in children undergoing chemotherapy who are at risk of a serious infection called febrile neutropenia. About 30 children from families with social or emotional challenges will either use a wearable …

This early-phase trial tests a new therapy called TCR-T cells, which are immune cells engineered to recognize and attack cancer cells with specific KRAS mutations (G12V or G12D). The study will enroll 25 adults with advanced solid tumors (like colorectal or lung cancer) who have …

This study tests an experimental pill called ZL-85FA in people with advanced solid tumors (breast, ovarian, fallopian tube, primary peritoneal, or prostate cancer) that have not responded to standard treatments. The trial has two phases: first, finding a safe dose, then checking …

This early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…

This study tests a new drug, HX111, in about 70 people with advanced solid tumors or lymphoma that has not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and side eff…

This Phase 2 trial tests whether combining two platelet-boosting drugs (hetrombopag and rhTPO) works better than hetrombopag alone for cancer patients with dangerously low platelets from treatment. About 204 adults with solid tumors will be randomly assigned to one of the two gro…

This study looks at whether daily step counts can help monitor how well vulnerable patients with metastatic hormone-sensitive prostate cancer are doing on a combination of darolutamide and standard hormone therapy. About 80 adults who are frail or have other health issues will we…

This study tests an experimental oral drug called XNW34017 in 150 people with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors. It is an…

This study tests whether adding the heart medication propranolol to standard hormone therapy before prostate removal can improve outcomes for high-risk prostate cancer patients. About 30 men will receive the combination treatment for several weeks before surgery. The goal is to s…

This phase 2 trial tests whether adding dapagliflozin, a diabetes medication, to standard hormone therapy improves outcomes for men with metastatic castrate-resistant prostate cancer. About 60 participants will be randomly assigned to receive either the combination or standard ca…

This study tests a drug called ivarmacitinib in 72 people with advanced solid tumors who had to stop their cancer immunotherapy because of severe immune-related side effects. The goal is to see if the drug can control those side effects and, if successful, allow patients to safel…

This study tests a new approach for men with advanced prostate cancer that no longer responds to hormone therapy. It uses a special imaging agent to find cancer cells and a radioactive drug to destroy them. The goal is to see if the treatment is safe and shrinks tumors. About 49 …

This study tests several new anti-cancer drugs and technologies in 600 people with rare solid tumors that have spread or cannot be removed. Participants will receive treatments matched to their tumor's unique genetic profile. The goal is to see if these therapies are safe and shr…

This study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…

This study tests whether using PSMA-PET scans to guide radiation therapy can improve cancer control in men with high-risk prostate cancer that hasn't spread to lymph nodes. About 250 participants will receive radiation to the prostate and nearby tissues, with or without whole pel…

This phase 2 trial tests whether adding darolutamide (a pill that blocks male hormones) to standard hormone therapy after prostate removal can keep cancer from coming back in high-risk patients. About 40 men will take the combination for 12 months and be followed for 2 years. The…

This early-stage study tests a new treatment called KXV01 TCR Lentinvivo in 30 adults with advanced solid tumors that have not responded to standard therapies. The main goal is to check safety and find the right dose. The treatment uses a virus to deliver cancer-fighting genes in…

This trial tests a new imaging system that combines PSMA-PET, MRI, and ultrasound to guide robot-assisted prostate surgery. The goal is to help surgeons remove all cancer while sparing healthy tissue, nerves, and urinary control. About 98 men with prostate cancer will take part t…

This study looks at men with advanced prostate cancer that has spread to other parts of the body. After 6 months of hormone therapy, those whose scans show the cancer is well-controlled may either continue hormone therapy alone or also have their prostate removed. The goal is to …

This phase 2 trial tests a combination of PRaG-1 Cordycepin Tablets (from a fungus), radiation therapy, immune-boosting injections, and immunotherapy drugs in 65 adults with advanced solid tumors who have no standard treatment options. The goal is to see if this mix improves immu…

This early-stage trial tests an experimental drug called ACC-1898, taken as a daily pill, in adults with advanced solid tumors (like liver, kidney, or stomach cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see how the body handl…

This early-phase trial tests a new drug called TB511 in people with advanced solid tumors (lung, prostate, colorectal, or liver cancer) that have stopped responding to standard care. The study has two parts: first, finding the safest dose of TB511 alone; second, testing TB511 com…

This early-stage trial tests the safety of combining a targeted radiation drug (lutetium DGUL) with an immunotherapy (pembrolizumab) in 30 men with metastatic castration-resistant prostate cancer. Participants receive either the radiation drug alone or both drugs together. The go…

This study tests a new mRNA vaccine designed to help the immune system attack cancer cells. The vaccine targets a protein found only in tumors and is given together with an immunotherapy drug (anti-PD-1). About 60 adults with advanced solid tumors that cannot be removed by surger…

This phase 2 trial tests whether memantine hydrochloride, a drug used for Alzheimer's, can help control advanced prostate cancer that has stopped responding to standard hormone therapy. Fifteen men with metastatic castration-resistant prostate cancer will take memantine alongside…

This study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…

This study tests if the antibiotic trimethoprim can safely lower folate levels in men starting hormone therapy for advanced prostate cancer. About 50 men will take the drug daily for 3 months to see if it helps control the disease. The goal is to find a safer, more effective way …

This early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…

This study looks at giving the drug rezvilutamide to men with high-risk or locally advanced prostate cancer before their surgery. The goal is to see if it can completely clear cancer cells from the removed tissue and reduce the chance of the cancer coming back. About 115 particip…

This early-phase study tests a new treatment called KXV01 TCR Lentinvivo for people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety and find the right dose. About 30 adults aged 18 to 70 will take part, and researchers …

This early-stage study tests a new drug, ATB-320, in 24 adults with solid tumors that have spread or are getting worse despite standard treatments. The main goal is to find a safe dose and check for side effects. Participants must provide tumor samples and have tumors that can be…

This study tests an experimental oral drug called GFH276 in people with advanced solid tumors that have RAS mutations, including pancreatic, lung, and colorectal cancers. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks if the drug shrinks tumors. About …

This early-phase trial tests a personalized gene therapy called KXV01 TCR Lentinvivo Injection for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a virus to deliver cancer-fighting genes into the patient's own immune cells. The …

This study tests a drug called Romiplostim N01 in 106 cancer patients whose platelets drop due to chemo, radiation, or immunotherapy. The goal is to see if it can safely raise platelet counts better than the current standard treatment. Patients will be randomly assigned to receiv…

This trial tests an experimental oral drug called TQB3201 in people with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. The drug works by breaking down a key protein that fuels cancer growth, even in cancers with resistance mutat…

This early-phase trial is testing a combination of two experimental drugs, IMM2510 and IMM01, in about 104 people with advanced solid tumors that have already been treated. The goal is to find safe doses and see if the combination can shrink tumors. The study is not yet recruitin…

This study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…

This phase 2 trial tests whether romiplostim N01 can safely raise low platelet counts in 60 adults with solid tumors who have had radiotherapy combined with other treatments. The main goal is to see if platelet counts increase by at least 50 billion per liter within two weeks. Th…

This study compares a precise, focused radiation treatment (stereotactic body radiotherapy) to simply watching the cancer (active surveillance) in men with low-to-intermediate risk prostate cancer. The goal is to see if the radiation can reduce the number of men who later need st…

This trial is testing an experimental imaging agent called [⁶⁴Cu]Cu-RAX301, which is designed to bind to prostate cancer cells and show up on PET/CT scans. The study includes men with prostate cancer who are either about to have surgery to remove the prostate or who may have a re…

This pilot study investigates whether a PSMA PET scan, using an injected radiotracer, can detect clinically significant prostate cancer recurrence one year after focal HIFU treatment, compared with the standard MRI. About 30 men with prostate cancer who meet specific criteria wil…

This trial investigates whether Posluma, a PSMA-targeted PET scan, can accurately detect any remaining or returning prostate cancer about 12 months after focal therapy. Researchers will compare the scan results with MRI and biopsy data in 22 men with intermediate-risk, organ-conf…

This study tests a new AI framework called Cad-MMFF that combines clinical information, ultrasound, and MRI images to better detect clinically significant prostate cancer. The goal is to see if this approach can reduce unnecessary biopsies and safely limit the use of MRI. The stu…

This study is testing whether a new scoring system, called the Fusion CEMEP score, can safely guide prostate biopsy decisions. The goal is to see if men with suspected prostate cancer can skip the extra systematic biopsies and only have targeted biopsies based on MRI findings. Th…

This pilot study is testing whether a special PET/MRI scan using a radioactive tracer called 68Ga-PSMA-11 can better identify all areas of significant prostate cancer in men with localized disease. The goal is to improve selection for focal therapy, a treatment that targets only …

This trial tests whether a fluorescent dye called zopocianine can make prostate cancer cells glow under near-infrared light during surgery. Men with prostate cancer scheduled for prostatectomy receive a single dose of the dye before surgery. The goal is to see if the dye helps su…

This trial tests whether a new imaging agent called INR 202, used with a PET/CT scan, can detect more tumors than the standard FDG-PET/CT in people with advanced solid tumors. Thirty adults with advanced cancer will receive both scans to compare how many lesions each method finds…

This trial is testing whether a special PET scan (FTT-PET) and a blood test that looks for tumor DNA (ctDNA) can predict how well men with metastatic prostate cancer will respond to PARP inhibitor therapy. The study will enroll about 75 men whose cancers have certain genetic muta…

This study explores whether measuring radioactive counts from PSMA PET/CT-guided biopsy samples can instantly tell if a tissue core contains cancer. Researchers aim to find a cutoff value that reliably distinguishes cancerous from non-cancerous tissue, using standard pathology as…

This study tests a new imaging tracer called [18F]FAPI-74, which attaches to a protein found on cells in tumors and scarred or inflamed tissue. Researchers want to see if it can show these areas more clearly than current scans. About 770 adults with various cancers or non-cancer …

This study tests a new infrared fluorescence staining technique that could help doctors diagnose prostate cancer faster during a biopsy. The method is compared to the standard frozen section analysis and the gold-standard paraffin section. If successful, it may offer a quicker, m…

This study compares an AI algorithm to radiologists in reading prostate MRI scans to detect clinically significant prostate cancer. About 500 men with suspected prostate cancer will have their MRI read by both AI and a radiologist, and results will be compared. If the AI performs…

This study compares robotic-assisted prostate biopsy to expert manual biopsy in 570 men with high BMI and suspicious MRI findings. The robot locks the needle in place to avoid hand tremors and improve accuracy. The main goal is to see if the robot detects more clinically signific…

This study tests a new PET/CT imaging agent called 68Ga-NYM032 in 232 men with suspected prostate cancer recurrence after initial treatment. Participants have rising PSA levels, and the scan aims to accurately locate any remaining cancer. The goal is to see how well the scan dete…

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This study will test a new urine test called My Prostate Score 2 (MPS2) combined with MRI to detect aggressive prostate cancer in men aged 50-75 with elevated PSA levels. The goal is to find only the cancers that need treatment and avoid unnecessary biopsies. The trial plans to e…

This phase 2 trial tests whether a new radioactive imaging agent, 61Cu-NU101, can detect prostate cancer spread as well as or better than the current standard, Pylarify. 34 men with confirmed prostate cancer and visible disease on a prior Pylarify scan will receive one dose of 61…

This study compares a special ultrasound (mp-US) with contrast dye to standard MRI for finding prostate cancer. About 300 men scheduled for a biopsy will get both scans to see if the ultrasound can guide biopsies just as well as MRI. The goal is to offer a simpler, cheaper option…

This study tests whether a special PET scan using fluciclovine can help doctors decide on treatment for men whose prostate cancer has returned after initial treatment, but whose standard PSMA PET scan was unclear or negative. About 142 men will receive the fluciclovine PET scan, …

This study tests a workshop led by peers and a Black GP to encourage Black men aged 45 and over to talk to their doctor about prostate cancer risk and get a PSA test. About 300 men from three UK regions will take part. Half attend the workshop right away, the other half wait six …

This study tests whether a new type of ultrasound, called transperineal micro-ultrasound, can better detect prostate cancer during biopsy. Unlike standard ultrasound, this method uses higher frequency sound waves to create clearer images. Researchers will enroll 138 men scheduled…

This study compares a new, stronger 7 Tesla MRI to the standard 3 Tesla MRI for finding suspicious spots in the prostate. Researchers want to see if the stronger scanner can detect problems more clearly and possibly without using a contrast dye. About 200 men will get both scans …

This pilot study tests a new high-resolution PET-CT scan done during prostate cancer surgery to see if it can better detect cancer cells left behind or spread to lymph nodes. Ten men with high-risk prostate cancer will receive a special tracer injection before surgery, then get s…

This study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…

This phase 2 trial will test whether a special PET scan using Flotufolastat F18 can accurately detect any remaining prostate cancer after focal therapy (like cryotherapy or HIFU). About 60 men with prostate cancer who haven't had prior treatment will get the scan before and after…

This study tests a special microscope that lets surgeons check for leftover cancer cells right after removing the prostate. It involves 20 men with prostate cancer who are already scheduled for surgery. The goal is to see if the microscope can accurately find cancer at the edges …

This study tests a new PET scanner built specifically to image the prostate. Researchers want to see if it can detect prostate cancer more clearly than standard whole-body PET scans. About 25 men with known or suspected prostate cancer will receive both scans, and the images will…

This study will compare a newer imaging method called 18F-PSMA PET/CT with the standard CT scan for prostate cancer patients. The goal is to see if the new scan is better at finding cancer initially, checking how well treatment is working, and detecting cancer that has come back.…

This study looks at whether a blood test, called the RILA assay, can predict which prostate cancer patients will have late side effects from a precise type of radiation therapy (SBRT). About 220 men with low- or intermediate-risk prostate cancer will give a blood sample before tr…

This study explores whether analyzing tumor DNA in urine can be a simple, non-invasive way to monitor prostate and bladder cancer. Researchers will collect urine samples from 25 patients at different treatment stages to see if the test can detect cancer mutations and track change…

This study is testing a new blood test called PROSTest to see if it can accurately detect prostate cancer in men with high PSA levels. Researchers will compare the test results with standard prostate biopsy findings in 1,500 men. If the test works well, it could help many men avo…

This study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…

This study will follow 1,000 men with suspicious prostate lesions using yearly MRI scans and regular PSA blood tests. The goal is to see if changes in MRI images can help decide when a biopsy is truly needed, potentially avoiding unnecessary procedures. Researchers will track how…

This phase 2 trial tests a fluorescent dye called DGPR1008 that targets prostate cancer cells. Before robot-assisted prostate removal surgery, 18 men with prostate cancer will receive an injection of the dye. During surgery, a special camera will make cancer cells glow, helping s…

This study looks at whether adding a special PET scan (18F-PSMA) to an MRI can find more serious prostate cancers in men whose MRI results are unclear. About 250 men with suspicious but not definitive MRI scans will be randomly assigned to get either an MRI-guided biopsy alone or…

This study tests whether a high-resolution ultrasound technique, called micro-ultrasound, can find aggressive prostate cancers that standard MRI might miss. Researchers will enroll 90 men with low-risk prostate cancer who have negative or stable MRI results. Participants will get…

This study tests a special dye called DGPR1008 that makes prostate cancer cells glow under near-infrared light during surgery. About 27 men with prostate cancer will receive the dye before their prostate removal surgery. The goal is to see if the dye helps surgeons find and remov…

This study tests an artificial intelligence (AI) model that uses images from prostate biopsies to predict when prostate cancer will become resistant to hormone therapy. Researchers will enroll 150 patients with intermediate- to high-risk prostate cancer who are starting hormone t…

This study tests three new radioactive imaging agents against a standard one for PET/CT scans in 9 men with advanced prostate cancer. The goal is to see which agent best highlights cancer lesions in the body. It is an early-stage imaging study, not a treatment trial.

This study tests a new way to detect prostate cancer early by looking at changes in MRI scans over time instead of relying on a single scan. About 380 men with suspicious MRI findings will be followed to see if this approach reduces unnecessary biopsies and over-treatment. The go…

This study compares two ways of taking prostate biopsies in men with suspected prostate cancer. The new method takes samples from the MRI-visible spot and nearby areas, while the standard method also samples random spots across the prostate. The goal is to see if the new approach…

This study compares two ways to diagnose bleeding problems during surgery: a quick bedside test (viscoelastic test) and standard lab tests. The goal is to see which method gives faster results, helping doctors treat bleeding sooner. About 210 adults having high-risk surgeries (li…

This study is developing a new blood test that combines quantum sensors and artificial intelligence to detect prostate cancer. Researchers will analyze DNA fragments in blood samples from 1100 men to train an AI model. The goal is to create a non-invasive, accurate diagnostic too…

This study tests a new way to diagnose prostate cancer using PSA tests, digital rectal exams, and MRI scans. Men aged 50-75 with elevated PSA or suspicious exams will get an MRI first. Only those with suspicious MRI results will have a biopsy, and they will be randomly assigned t…

This phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…

This study tests whether practicing deep breathing exercises before surgery can lower the chance of postoperative delirium—a state of confusion and disorientation—in men undergoing robot-assisted prostate removal for prostate cancer. Half of the 50 participants will be taught a s…

This study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…

This study tests whether a non-invasive brain stimulation technique called transcranial magnetic stimulation (TMS) can prevent postoperative delirium in elderly patients undergoing urological surgery. Researchers will apply TMS to the left frontal lobe during anesthesia and monit…

This study tests whether the supplement glutamine can prevent nerve damage caused by the chemotherapy drug vincristine in children and teens with cancer. About 70 participants, aged 6 to 18, will take glutamine twice daily for 14 days during their treatment. Researchers will trac…

This trial tests whether an artificial intelligence chatbot can help men with prostate cancer better understand radiation therapy. Participants will use a plain-language chatbot alongside standard education from their care team. Researchers will measure changes in patients' confi…

This pilot trial tests a program called FamilyStrong, designed to help family caregivers of people with advanced cancer manage their own distress. Caregivers receive monthly phone calls from a trained lay navigator who screens for stress, identifies their biggest concerns, and of…

This study tests whether adding estrogen to standard prostate cancer treatment can improve quality of life for 60 men with metastatic hormone-sensitive prostate cancer. Standard therapy often causes hot flashes and other side effects by lowering estrogen. The study compares estro…

This phase 2 trial tests whether a low dose of naltrexone (LDN) can reduce fatigue in men with prostate cancer who are on hormone therapy (ADT). The study will enroll 60 participants and measure fatigue, quality of life, and safety. It is not yet recruiting.

This study tests whether adding telehealth sex therapy to standard pelvic floor physical therapy helps men recover urinary and sexual function after prostate cancer treatment. All participants receive pelvic floor therapy and education on using a vacuum erection device. Half are …

This pilot study tests whether high-intensity interval training (HIIT) before prostate removal surgery can improve recovery and reduce anxiety. Men scheduled for radical prostatectomy will do vigorous exercise for about 60 minutes per week for at least four weeks before their ope…

This study tests whether an AI-powered program can help older adults with serious illnesses like cancer or heart disease manage emotional distress. Participants receive short videos and daily check-ins from a chatbot that teaches practical coping skills, all from their own phone.…

This trial tests whether mind-body practices like breathwork, meditation, and gentle yoga can improve quality of life, stress, and sleep in people who have recently finished cancer treatment. Participants will practice these techniques weekly for six weeks while wearing an activi…

This trial tests whether regular text-message check-ins can help advanced cancer patients get palliative care support earlier. Patients receive a text every two weeks asking them to rate their symptoms online. If any symptoms are concerning, a coordinator calls to assess and mana…

This study tests a program called SUFICS-PACT for prostate cancer survivors who have sexual or urinary problems after treatment. The program includes screening, counseling from mental health professionals, and close follow-up. About 200 participants will be randomly assigned to r…

This study tests a program that pairs veterans with advanced cancer with a lay health worker who helps them discuss their goals and preferences for care with their doctors. The goal is to increase the number of veterans who have these important conversations and document their wi…

This trial tests an 8-week eHealth program called eMindExCare that combines mindfulness practices with home-based aerobic and resistance exercises for prostate cancer patients undergoing active treatment. The study aims to see if the program is feasible and acceptable, and whethe…

This trial tests whether a wearable device that delivers a cooling sensation on the wrist can reduce the burden of hot flashes in men with prostate cancer who are on androgen deprivation therapy (ADT). About 66 participants will be randomly assigned to use the device right away o…

This study tests whether acupuncture can reduce hot flashes in 40 men with prostate cancer who are on hormone therapy. Hot flashes are a common side effect that can disrupt sleep and daily life. Participants will receive real or sham acupuncture, and researchers will track change…

This trial investigates whether a supervised program of aerobic and strength training can improve quality of life, heart function, and body composition in men with prostate cancer who are receiving androgen deprivation therapy (hormone therapy). The study involves 46 men aged 40 …

This pilot study tests a communication skills training program called Starting the Conversation for prostate cancer patients who are bothered by sexual problems. About 100 men will either receive the training or a general health education program. The goal is to see if the traini…

This study tests if eating only within an 8-hour window each day (time-restricted eating) can reduce treatment side effects and improve quality of life for people with solid tumors starting adjuvant therapy after surgery. Fifty adults will be randomly assigned to follow this eati…

This study compares two types of radiation therapy for prostate cancer: one that boosts the whole prostate gland and one that boosts only the main tumor. About 186 men will be randomly assigned to one of the two treatments. The goal is to see which approach causes fewer urinary a…

This study tests a web-based program designed to help caregivers of prostate cancer patients deal with uncertainty and reduce the burden of caregiving. The program is based on a theory about how people handle uncertainty in illness. Researchers will measure changes in caregivers'…

This study tests whether taking high doses of vitamin E and CoQ10 daily for 90 days can reduce chronic side effects from pelvic radiation in people treated for prostate, uterine, cervical, or anal cancer. Researchers will monitor safety, side effects, and quality of life in 200 a…

This study tests whether sucking on ice chips during chemotherapy can prevent or reduce the severity of painful mouth sores (oral mucositis) in cancer patients. 102 adults receiving 5-fluorouracil or methotrexate will be randomly assigned to either get ice chips during infusion p…

This study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …

This study tests whether a 12-week exercise program, delivered via Zoom, is practical and helpful for older adults (65+) with cancer who live in rural areas. Participants will do two supervised exercise sessions per week. The goal is to see if the program improves quality of life…

This study looks at whether teaching pelvic floor muscle exercises before and after prostate removal surgery can help men control urine leakage and feel better day-to-day. Ten men who have surgery for prostate cancer will learn these exercises from nurses. The goal is to see if t…

This study will test whether a focal microwave ablation procedure for localized prostate cancer can be performed under local anesthesia instead of general anesthesia or deep sedation. Twenty eligible patients will undergo the treatment while awake, and researchers will measure ho…

This study tests if fezolinetant can reduce hot flashes in men receiving hormone therapy for prostate cancer. About 54 men will take either the drug or a placebo, and track their hot flash severity and quality of life. The goal is to ease this common side effect without affecting…

This study tests whether a 15-minute hand and foot exercise routine can reduce nerve pain caused by Taxane chemotherapy in cancer patients. Fifty-eight adults with mild nerve symptoms will either do the exercises plus standard care or receive standard care alone. Researchers will…

This pilot study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in people with solid tumors undergoing cancer treatment. About 45 adults will take one mini-square before each meal for 90 days. The goal is to see if this simple supplement can ease a…

This study develops and tests a support program for cancer survivors who worry about their cancer returning. 150 adults who finished treatment for breast, head and neck, colon-rectal, or prostate cancer will join. Depending on their level of fear, they will receive education, psy…

This study tests a virtual reality assistant called ViRA designed to provide emotional support and help with daily needs like food and transportation for Black men recently diagnosed with prostate cancer. About 200 participants will use the ViRA app and researchers will measure h…

This study follows 130 men with unfavorable intermediate-risk prostate cancer to see how a combination of targeted radiation (SBRT) and 6 months of hormone therapy (ADT) impacts their sexual function. Researchers measure erectile function before treatment and again after 24 month…

This pilot study will test whether a live, supervised exercise program done at home via video is feasible and helpful for World Trade Center responders who have had prostate cancer. Forty participants will be randomly assigned to either the 16-week exercise program or a waitlist.…

This study tests whether a traditional Chinese medicine hand-foot soak can reduce nerve pain and skin reactions caused by chemotherapy. About 300 adults with solid tumors who have these side effects will use the soak. The goal is to see if it improves symptoms and quality of life…

This study tests a daily digital mindfulness program designed to reduce depressive symptoms in people who have completed treatment for breast, prostate, or colorectal cancer. Researchers will enroll 76 participants with mild to moderate depression to see if the program is feasibl…

This study tests whether a more targeted (focal) radiation boost can better preserve urinary quality of life compared to standard whole gland treatment in men with intermediate- or high-risk prostate cancer. About 58 participants will receive either focal or whole gland high dose…

This study tests a web-based program called SCIPI that provides men with localized prostate cancer easy-to-understand information, communication tools, and social support. About 200 newly diagnosed patients will be randomly assigned to use SCIPI or receive usual care. Researchers…

This study tests whether adding electroacupuncture to standard local anesthesia can lower pain and anxiety in men undergoing a prostate biopsy. 190 participants will receive either real or sham electroacupuncture during the procedure. The goal is to see if this ancient technique …

This study tests whether virtual palliative care (via video calls) works as well as standard in-person care for adults with cancer. About 252 participants will be randomly assigned to one of the two approaches. Researchers will measure quality of life, symptom burden, and satisfa…

This study tests whether a procedure called prostate artery embolization (PAE) can reduce urinary side effects from radiotherapy in men with prostate cancer. Participants have large prostates or existing urinary symptoms. They will receive PAE before starting radiation, and resea…

This study tests whether early electroacupuncture (a type of acupuncture with mild electric pulses) can help men regain bladder control after prostate cancer surgery. About 216 men aged 18 to 80 will receive either real or fake electroacupuncture three times a week for six weeks,…

This study tests whether starting acupuncture before the urinary catheter is removed can help men regain bladder control faster after prostate cancer surgery. 144 men will be randomly assigned to receive either real electroacupuncture or a sham (fake) version. The main goal is to…

This study tests whether listening to music during a transperineal prostate biopsy can lower pain and anxiety. About 78 men over age 50 with suspected prostate cancer will be randomly assigned to have music or no music during the procedure. The goal is to see if music helps patie…

This study compares the side effects of two radiation treatments for men with low-to-intermediate risk prostate cancer: low dose rate brachytherapy (radioactive seeds placed in the prostate) and ultra-hypofractionated radiotherapy (5 sessions of external radiation over 2 weeks). …

This study will compare how men with intermediate-risk prostate cancer feel about their quality of life after either total prostate removal (surgery) or a less invasive treatment called focal HIFU (high-intensity focused ultrasound). About 100 sexually active men aged 40-75 will …

This study will test whether an internet-based yoga program can help men with prostate cancer manage stress, urinary problems, and quality of life. 220 men who have been treated for prostate cancer will be randomly assigned to either the digital yoga program or standard care. The…

This study aims to understand how migration history and social factors affect the quality of life of Black immigrant men from Sub-Saharan Africa and the Caribbean who have been diagnosed with prostate cancer. Researchers will interview 40 men to learn about their experiences and …

This pilot trial tests whether a risk calculator designed for Nigerian men can help primary care providers better identify those with clinically significant prostate cancer. Researchers will train healthcare workers at community hospitals and then support them in using the tool f…

This trial explores whether a whole-body bone scan (SPECT/CT) taken in the treatment position can help doctors plan stereotactic radiotherapy more precisely for prostate cancer that has spread to the bones. Thirty patients will receive the scan in addition to standard imaging, an…

This study will test whether a special MRI scan (CSE-MRI) can accurately measure active bone marrow in men with metastatic prostate cancer, compared to a standard PET scan using a radioactive tracer (FLT). Fifteen participants will receive both scans at the same time using a comb…

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…

This study looks at how a short, home-based high-intensity workout affects steroid hormones in men with low-grade prostate cancer who are on active surveillance. About 49 men will do one supervised bodyweight HIIT session and provide saliva samples. The goal is to see if the exer…

This study is developing an artificial intelligence system that measures changes in total tumor volume from CT or MRI scans to see if it can predict survival better than the current standard method, which measures just a few tumors. Researchers will analyze data from about 6,000 …

This study collects blood samples from people with cancer or at high risk for cancer to create a large, well-organized repository for research. The goal is to provide scientists with a valuable resource to study cancer through liquid biopsies, which may lead to better detection a…

This study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…

This study looks at men with localized prostate cancer who had robot-assisted surgery to remove the prostate. The goal is to find which factors—like PSA levels, tumor grade, or MRI results—best predict whether the cancer will come back (called biochemical recurrence). Researchers…

This study explores whether artificial intelligence can help perform high-field whole-body MRI scans faster while keeping image quality high. Researchers will compare standard MRI sequences with AI-accelerated versions in 600 adults undergoing screening for prostate, lung, or vas…

This study looks at whether taking bicalutamide for two weeks can make PSMA PET/CT scans better at finding small amounts of prostate cancer that standard scans might miss. It involves 20 men with recurrent prostate cancer and very low PSA levels. Participants are randomly assigne…

This study observes how well a combination of two drugs, olaparib and abiraterone, works as a first treatment for men with metastatic castration-resistant prostate cancer who have already tried other hormone therapies. Researchers will track how long patients stay on the treatmen…

This study tests whether the Stockholm3 blood test can accurately detect when low-risk prostate cancer becomes more aggressive in men who are closely monitored instead of treated immediately. Researchers will enroll 350 men on active surveillance to see if the test can reduce the…

This study will send different types of WhatsApp messages to 235,000 people in Chile who are due for cancer or chronic disease screenings. Researchers want to see if the way a message is worded (basic, risk-focused, or peace-of-mind) and whether it mentions one test or both tests…

This study tests whether injecting a radioactive tracer directly into the prostate artery improves imaging compared to standard arm injection in 10 men with high-risk prostate cancer. The goal is to see if this method gives clearer pictures and helps predict the right radiation d…

This study will look at whether SPECT scans taken after Lu-PSMA therapy can help predict how well patients with metastatic castration-resistant prostate cancer (mCRPC) are doing. Researchers will measure tumor activity and volume on the scans and compare them to standard PET-base…

This study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…

This study looks at how Black and Hispanic adults in the U.S. feel about online information on prostate cancer. Participants will view a video or text post about the disease and then fill out a short survey. The goal is to understand trust and emotional reactions to online health…

This study tests whether trained veteran peer navigators can help men aged 40-69 make informed choices about PSA screening for prostate cancer. Participants will receive a decision coaching session to understand the pros and cons of screening. The goal is to see if this approach …

This study looks at the best way to help prostate cancer survivors learn about and get genetic testing for inherited cancer risks. About 500 participants will be randomly assigned to a digital guide, a printed guide, or standard care. Researchers will track who requests testing a…

This study will compare two types of robot-assisted surgery for prostate or kidney cancer: single-port (one small incision) and multi-port (several incisions). Researchers will track 376 adults to see which approach leads to a shorter hospital stay and better recovery. The study …

This study tests whether a new real-time imaging method can make radiation therapy more accurate for cancer patients. About 40 adults with various cancers will receive their normal radiation treatment while the new imaging tracks the tumor in real time. The goal is to see if the …

This study looks at how a person's body composition—like muscle and fat levels—affects the radiation dose delivered to tumors and healthy organs during a targeted therapy for advanced prostate cancer. About 100 men with a specific type of prostate cancer will receive the standard…

This early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…

This study will compare how much pain men expect versus actually feel during two common prostate biopsy methods: transrectal and transperineal. About 200 men having their first prostate biopsy will rate their pain before and after the procedure. The goal is to help doctors choose…

This study tests a plastic scintillation detector that can monitor radiation dose and source position in real time during brachytherapy for prostate and gynecologic cancers. The goal is to see if the device can be used without disrupting the treatment workflow. If it works, it co…

This study aims to learn about genetic changes in metastatic prostate cancer and how they affect patient outcomes. Researchers will collect and analyze tissue and blood samples from 100 adults in Brazil who are receiving standard palliative therapy. The goal is to better understa…

This study will follow 700 men with high-risk localized or metastatic prostate cancer to collect detailed information on how they are treated in everyday practice. Researchers will track treatments, side effects, quality of life, and disease progression over time. The goal is to …

This study will test whether ChatGPT, an artificial intelligence chatbot, can help men better understand their prostate cancer diagnosis. Fifty men who recently had a prostate biopsy will use the chatbot to review their pathology results. Researchers will measure how accurately p…

This study looks at whether a blood test can predict how well certain cancer drugs (PARP inhibitors) work in people with advanced breast, prostate, ovarian, or pancreatic cancer. Researchers will collect blood and tumor samples from 300 adults to analyze cancer cells and their DN…

This study looks at two different gas flow levels (low vs. minimal) for the anesthesia drug sevoflurane during robot-assisted prostate cancer surgery. The goal is to see which flow rate better maintains healthy breathing and oxygen levels during the procedure. About 70 men having…

The BALANCE study is a research project that asks Black and mixed-ancestry men with prostate cancer about their quality of life after treatment. Researchers want to learn how different treatments affect physical health, mental health, and daily life in these communities. By colle…

This study will compare four different ways of following up with men after they have been treated for prostate cancer: hospital visits, GP visits, shared care, or self-management. The goal is to see which approach is safest, most effective, and makes the best use of NHS resources…

This phase 2 trial is testing four different doses of enzalutamide (40, 80, 120, and 160 mg) in men aged 75 and older with advanced prostate cancer. The goal is to see how drug levels in the blood differ between older and younger patients, and to find the safest and most effectiv…

This study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…

This study will observe how the drug lutetium-177 vipivotide tetraxetan is actually used in patients with metastatic prostate cancer. Researchers will collect data from medical records across multiple countries, using AI to analyze treatment patterns and outcomes. The goal is to …

This study looks for biological markers in tumor tissue and blood that may be linked to anxiety and depression in people with solid tumors. Researchers will combine psychological assessments with lab tests to better understand these emotional struggles. The goal is to improve ear…

This study is testing a co-created digital health literacy tool designed to help people better understand prostate cancer prevention and care. Researchers will enroll 3,100 adults aged 40 and older, including patients, caregivers, and healthcare professionals, across six European…

This study will interview 120 cancer patients in Texas to learn what makes it easier or harder to get timely cancer treatment. Researchers will talk with patients by phone or video to understand their experiences across different cancer types and insurance plans. The goal is to i…

This study looks at what helps or hinders prostate cancer patients from completing genetic testing. Researchers will develop and test a decision support tool to educate patients and help them decide about testing. The goal is to increase testing rates, which can guide treatment a…

This study aims to understand why some communities, including Black men, transgender individuals, and those with limited healthcare access, are less likely to use prostate cancer genetics services. Researchers will interview about 100 people to identify barriers and then work wit…

This study looks at whether a test called minimal residual disease (MRD) can help predict how well treatment works in men with metastatic hormone-sensitive prostate cancer. Researchers will track 50 newly diagnosed patients to see how different gene patterns affect treatment resp…

This observational study will measure how well the body breaks down blood clots in 150 cancer patients (with blood cancers or solid tumors) who also have clotting issues. Researchers will take extra blood samples during routine care to look for markers that might predict bleeding…

This study looks at whether a blood test for circulating tumor DNA (ctDNA) can detect leftover cancer after surgery in people with breast, lung, prostate, ovarian, or stomach cancer. About 840 participants will give blood samples before and after standard treatments. No new treat…

This study looks at whether having an orgasm within 36 hours before prostate cancer surgery makes the seminal vesicles smaller and easier for the surgeon to remove. About 40 men will be randomly assigned to either ejaculate or abstain for at least 72 hours before their operation.…

This study creates a registry of 500 cancer patients receiving immunotherapy to better understand and manage immune-related side effects (irAEs). Researchers will collect data on who gets these side effects, how they present, and what treatments work best. The goal is to improve …

This study aims to adapt a questionnaire called PROFFIT, originally developed in Italy, to measure financial toxicity (the financial burden of cancer treatment) in Turkish patients. Researchers will enroll 320 adults with cancer who have received treatment in the last three month…

This observational study looks at how immune checkpoint inhibitors (a type of cancer immunotherapy) affect ovarian function and fertility in women aged 18-38 with solid tumors. Researchers will collect blood and stool samples before and during treatment to measure hormone levels …

This study will observe 300 people with advanced lung or gastrointestinal cancers who receive adebrelimab combined with other treatments. Researchers will track side effects and how well the cancer responds. It is a real-world study, meaning it watches what happens in regular med…

This study will follow 396 men with metastatic hormone-sensitive prostate cancer to understand how the disease changes over time and becomes resistant to therapy. Participants receive standard treatments like abiraterone plus hormone therapy, and researchers will analyze genetic …

This study will test a new automated blood test that measures how well a patient's T-cells (immune cells) are working. The goal is to see if the test results match how well the cancer responds to standard immunotherapy drugs like anti-PD1 or anti-CTLA4. The study will include 100…